Spark Microgravity

Executive Summary

Spark Microgravity operates the world’s first orbital space laboratory for pharmaceutical R&D, enabling drug discovery and biologics research in microgravity. Founded in 2018 and headquartered in Hamburg, Germany, the company provides end-to-end mission services including experiment design, payload integration, launch coordination, and on-orbit support. By leveraging the unique environment of microgravity, Spark enables researchers to study protein crystallization, cell behavior, and drug formulations in ways not possible on Earth, potentially accelerating the development of new therapies. The company targets pre-clinical and early-stage biopharma clients, offering a scalable platform for microgravity-based experimentation.

Upcoming Catalysts (preview)

• Q3 2026First Commercial Payload Launch75% success
• Q4 2026Pharmaceutical Partnership Announcement60% success
• Q1 2027Series A Funding Round50% success